Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHAA4549A in acute uncomplicated seasonal influenza A
NCT02623322Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of vedolizumab in Influenza A (IAV), sponsored by Genentech. Started Oct 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02623322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623322.